Project 3 (fMRI) will gather functional magnetic resonance imaging measures in two cohorts of subjects, in order to determine early prognostic factors for the development of Alzheimer's disease (AD). Both cohorts will consist of controls (CDR=0) and subjects with """"""""questionable"""""""" AD (CDR=0.05). Participants will be evaluated at Baseline (Time 1) by fMRI and will be followed to determine changes in functional status. A subset will also be reevaluated at a second time point. At both assessments, Project 3 will utilize a memory task to activate specific brain systems and detect these changes with fMRI. Based on findings from within the Program Project, as well as from findings in the literature, it is hypothesized that fMRI measurements in selected brain regions (e.e., the hippocampal formation, the anterior and posterior cingulate, the anterior thalamus and prefrontal regions) will be prognostic markers of which """"""""questionable"""""""" subjects develop AD over time. We will also examine the relationship between fMRI and measures from the other Projects, including neuropsychological test scores, single photon emission computed tomography (SPECT) and genetic data.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG004953-17
Application #
6336184
Study Section
Project Start
2000-08-01
Project End
2001-07-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
17
Fiscal Year
2000
Total Cost
$220,727
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Tosto, Giuseppe; Monsell, Sarah E; Hawes, Stephen E et al. (2016) Progression of Extrapyramidal Signs in Alzheimer's Disease: Clinical and Neuropathological Correlates. J Alzheimers Dis 49:1085-93
Herold, C; Hooli, B V; Mullin, K et al. (2016) Family-based association analyses of imputed genotypes reveal genome-wide significant association of Alzheimer's disease with OSBPL6, PTPRG, and PDCL3. Mol Psychiatry 21:1608-1612
D'Avanzo, Carla; Aronson, Jenna; Kim, Young Hye et al. (2015) Alzheimer's in 3D culture: challenges and perspectives. Bioessays 37:1139-48
Weissmiller, April M; Natera-Naranjo, Orlangie; Reyna, Sol M et al. (2015) A ?-secretase inhibitor, but not a ?-secretase modulator, induced defects in BDNF axonal trafficking and signaling: evidence for a role for APP. PLoS One 10:e0118379
Liu, Qing; Waltz, Shannon; Woodruff, Grace et al. (2014) Effect of potent ?-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers. JAMA Neurol 71:1481-9
Liang, Steven H; Yokell, Daniel L; Jackson, Raul N et al. (2014) Microfluidic continuous-flow radiosynthesis of [(18)F]FPEB suitable for human PET imaging. Medchemcomm 5:432-435
Choi, Se Hoon; Kim, Young Hye; Hebisch, Matthias et al. (2014) A three-dimensional human neural cell culture model of Alzheimer's disease. Nature 515:274-8
Macklin, Eric A; Blacker, Deborah; Hyman, Bradley T et al. (2013) Improved design of prodromal Alzheimer's disease trials through cohort enrichment and surrogate endpoints. J Alzheimers Dis 36:475-86
Johnson, Keith A; Sperling, Reisa A; Gidicsin, Christopher M et al. (2013) Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 9:S72-83
Fung, Wai Lun Alan; Naylor, Melissa G; Bennett, David A et al. (2013) Principal components methods for narrow-sense heritability in the analysis of multidimensional longitudinal cognitive phenotypes. Am J Med Genet B Neuropsychiatr Genet 162B:770-8

Showing the most recent 10 out of 104 publications